Prof. Kyu Joo Park (Seoul National University Hospital, Korea) reported a randomised controlled trial to assess the effectiveness of ramosetron, a serotonin (5-hydroxytryptamine [5-HT]3) receptor antagonist, for the treatment of anterior resection syndrome. Ramosetron significantly improved both the Low Anterior Resection Syndrome (LARS) score, as well as quality of life .
5-HT3 receptor antagonists are effective for the treatment of irritable bowel syndrome, in which exaggerated intestinal/colonic hypermotility is observed. Recent studies have suggested that the motility disorder, especially spastic hypermotility, seen in the neorectum following sphincter-preserving operations for rectal cancer may be the basis of the post-operative defecatory malfunction seen in in 60-90% of patients, and for whom there are no effective treatments.
The investigators wished to in...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« β-blockers may halt cirrhosis progression: PREDESCI trial Next Article
Phase 2 data shows benefit for mirikizumab in CD patients »
Table of Contents: UEGW 2019
Upper GI Disorders
Irritable Bowel Syndrome
Inflammatory Bowel Diseases
Microbiome and Microbiota
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.